Dosing warfarin should be based on genotyping for which genes?

Dosing warfarin should be based on genotyping for which genes?

• A. CYP2C9 and VKORC1
• B. ABCB1 and CYP3A4
• C. MTHFR and Factor II
• D. HLA-B*57:01 and G6PD

Answer: (A)

Genetic variation can shape both how quickly warfarin is cleared from the body and how sensitive a person is to its effects, which is crucial for a drug with a narrow therapeutic window. Warfarin’s active S-enantiomer is mainly metabolized by the enzyme produced by the CYP2C9 gene. Variants that reduce CYP2C9 activity slow metabolism, causing higher warfarin exposure and a greater risk of bleeding, so lower starting doses and slower titration are often needed for these individuals. Warfarin also targets the VKORC1 enzyme, which is essential for activating vitamin K dependent clotting factors. Polymorphisms in VKORC1 can decrease the amount of this enzyme, increasing sensitivity to warfarin and likewise necessitating a lower dose. Together, genotyping for these two genes helps tailor the initial dose more accurately and reduces time to reach the therapeutic INR. Other genes listed are not primary determinants of warfarin dosing. For example, ABCB1 and CYP3A4 have limited or less established roles in warfarin metabolism compared with CYP2C9; MTHFR and Factor II relate more to thrombosis risk than to dose requirements; HLA-B*57:01 and G6PD are linked to drug hypersensitivity or red blood cell enzyme problems, not warfarin dose guidance.

Genetic variation can shape both how quickly warfarin is cleared from the body and how sensitive a person is to its effects, which is crucial for a drug with a narrow therapeutic window. Warfarin’s active S-enantiomer is mainly metabolized by the enzyme produced by the CYP2C9 gene. Variants that reduce CYP2C9 activity slow metabolism, causing higher warfarin exposure and a greater risk of bleeding, so lower starting doses and slower titration are often needed for these individuals. Warfarin also targets the VKORC1 enzyme, which is essential for activating vitamin K dependent clotting factors. Polymorphisms in VKORC1 can decrease the amount of this enzyme, increasing sensitivity to warfarin and likewise necessitating a lower dose. Together, genotyping for these two genes helps tailor the initial dose more accurately and reduces time to reach the therapeutic INR.

Other genes listed are not primary determinants of warfarin dosing. For example, ABCB1 and CYP3A4 have limited or less established roles in warfarin metabolism compared with CYP2C9; MTHFR and Factor II relate more to thrombosis risk than to dose requirements; HLA-B*57:01 and G6PD are linked to drug hypersensitivity or red blood cell enzyme problems, not warfarin dose guidance.